<DOC>
	<DOCNO>NCT00671645</DOCNO>
	<brief_summary>- feasibility tolerance preoperative therapy Bevacizumab combination Capecitabine radiotherapy patient locally advance , locally operable rectal carcinoma - collection response rate ( T- M-downstaging , pathological complete remission )</brief_summary>
	<brief_title>Preoperative Combined RadioChemo-Molecular Target Therapy With Capecitabine , Bevacizumab , Radiotherapy</brief_title>
	<detailed_description>Combined RadioChemotherapy : Therapy start : within 28 day bioptical diagnosis Radiotherapy : 5 x 5 day 1.8 Gy radiotherapy ; cummulative dose 45 Gy Chemotherapy : Capecitabin 825mg/m² bid , radiation day first 4 week RCTx Molecular Targeted Therapy : Bevacizumab 5 mg/kg body weight ; day 1 , 15 , 29 Operation due TME adherence break min . 42 max . 56 day last application bevacizumab</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>age : 18 80 bioptical confirm adenocarcinoma rectum T3NxM0 status . The tumor basically surgically complete resectable ( &gt; R0 ) . former chemotherapy , radiotherapy pelvis abdomen and/or tumor resection rectum carcinoma WHO performance status 02 adequate bone marrow reserve ( granulocytes &gt; = 3.000/µl , absolute neutrophil &gt; = 0 1,5 x 10 9/l thrombocyte : &gt; = 100.000/µl , haemoglobin &gt; = 10g/dl ) adequate hepatic function ( Bilirubin : &lt; = 1.5 x ULN , GOT und GPT &lt; = 2.5 x ULN ) adequate renal function ( creatinin : &lt; = 1.25 mg/dl , creatininclearance : &gt; 50 ml/min ( Cockcroft Gault formula ) ) , proteinuria : dipstick &lt; 2+ . In case dipstick &gt; 2+ protein measure 24h urine exceed 1g/24h ) ability intake pill woman childbearing potential : exclusion pregnancy ( negative urin serum pregnancy test ) willingness woman childbearing potential accordingly potent men use approve contraceptive ( e.g . birthcontrol pill , loop , condom ) least 3 month conclusion study life expectancy least 3 month INR aPTT &lt; 1.5 ULN sign Informed Consent recruitment failure one inclusion criterion former radiotherapy pelvis abdomen former chemotherapy kind malign tumor last 5 year kind tumour last 5 year exception basal cell carcinoma skin cervix carcinoma situ general contraindication know hypersensitivity Bevacizumab and/or Capecitabine non malign disease , contraindication radiotherapy , chemotherapy Bevacizumab Capecitabine , resection rectum : uncontrolled hypertension ( systolic &gt; 150 mmHG and/or diastolic &gt; 100 mmHG ) clinical significant ( e.g . active ) cardiovascular disease : CVA ( cardiovascular accident ) / cerebral apoplexy ( &lt; 6 month recruitment ) , myocardial infarct ( &lt; 6 month recruitment ) , instable angina pectoris , CHF NYHA status II high , treat serious arrhythmia , hepatic disease , significant neurologic psychiatric disorder florid , serious infection time recruitment peripheral neuropathy ( NCI CTC &gt; = Grade 1 ) legally limited contractual capability evidence neurological psychiatric disease , constrict patient compliance opinion investigator evidence lack cooperation patient major intervention within 28 day recruitment , open wound serious injury , unhealed wound fracture patient spinal compression metastases central nervous system evidence bleed diathesis coagulation dysfunction actual intake anticoagulant thrombolytic agent , Aspirin &gt; 325 mg/d within 10 day study start ) actual recent ( within 10 day recruitment ) therapeutic therapy fullydosed anticoagulant . A prophylactic treatment permit . previous thromboembolic hemorrhagic event within last 6 month recruitment previous abdominal fistula , GI perforation intraabdominal abscess within last 6 month treatment study medication within 28 day recruitment patient malabsorption syndrome difficulty swallow pregnant breast feeding woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>pilot study</keyword>
	<keyword>rectal</keyword>
	<keyword>carcinoma</keyword>
	<keyword>phase II</keyword>
	<keyword>preoperative</keyword>
	<keyword>RadioChemo</keyword>
	<keyword>molecular</keyword>
	<keyword>target</keyword>
	<keyword>therapy</keyword>
	<keyword>T3</keyword>
	<keyword>ABCSG</keyword>
	<keyword>TAKO</keyword>
	<keyword>R04</keyword>
	<keyword>08</keyword>
</DOC>